硕肯生物硕肯生物Soken.bio
查看试用产品 →开放浏览 · 登录后申请
抗人 IMPA1 抗体对
试剂盒

抗人 IMPA1 抗体对

01AB01176

Inositol monophosphatase 1 (IMPA1) is an enzyme responsible for dephosphorylating myo-inositol monophosphate to generate free myo-inositol, which serves as a precursor for phosphatidylinositol synthesis. Located in the cytoplasm, IMPA1 plays a crucial role in maintaining normal brain function by providing inositol required for the synthesis of phosphatidylinositols and polyphosphoinositides. The enzyme is encoded by the IMPA1 gene in humans and is part of the essential phosphatidylinositol signaling pathway. In terms of disease associations, IMPA1 in promoting triple-negative breast cancer progression through its regulation of the mTOR pathway and epithelial-mesenchymal transition (EMT) process. Additionally, IMPA1 is a target of lithium, which inhibits the enzyme to induce autophagy, suggesting its potential involvement in mood disorders and other neuropsychiatric conditions for which lithium is prescribed.

Human
规格起售价
登录后可查看

技术参数

靶点基因名
IMPA1
基因别名
IMPA
蛋白别名
inositol monophosphatase 1; IMPA1
UniProt
P29218
物种
Human

产品详情

靶点名称
IMPA1
蛋白名称
inositol monophosphatase 1
蛋白别名
Inositol monophosphatase 1; IMP 1; IMPase 1; D-galactose 1-phosphate phosphatase; Inositol-1(or 4)-monophosphatase 1; Lithium-sensitive myo-inositol monophosphatase A1
靶点基因名
IMPA1
基因别名
IMPA
UniProt
P29218
来源物种
Homo sapiens (Human)
物种反应性
Human

背景介绍

Inositol monophosphatase 1 (IMPA1) is an enzyme responsible for dephosphorylating myo-inositol monophosphate to generate free myo-inositol, which serves as a precursor for phosphatidylinositol synthesis. Located in the cytoplasm, IMPA1 plays a crucial role in maintaining normal brain function by providing inositol required for the synthesis of phosphatidylinositols and polyphosphoinositides. The enzyme is encoded by the IMPA1 gene in humans and is part of the essential phosphatidylinositol signaling pathway. In terms of disease associations, IMPA1 in promoting triple-negative breast cancer progression through its regulation of the mTOR pathway and epithelial-mesenchymal transition (EMT) process. Additionally, IMPA1 is a target of lithium, which inhibits the enzyme to induce autophagy, suggesting its potential involvement in mood disorders and other neuropsychiatric conditions for which lithium is prescribed.